Chugai Plans May Enrollment Start for Actemra COVID-19 Trial, Aims for Approval by Year-End

Chugai Pharmaceutical plans to start enrolling patients in May for its Japan PIII trial for its anti-IL-6 receptor antibody Actemra (tocilizumab) for the treatment for COVID-19, according to its update on the Japic Clinical Trials Information database on April 28...read more